How does azacitidine modify dna rna in gvhd?

Azacitidine acts on both DNA and RNA, but its relevance to GVHD is mainly through DNA hypomethylation and the downstream immunomodulation.

How it works
- DNA mechanism (key for GVHD): After cellular activation, azacitidine is incorporated into DNA as 5-aza-dCTP and inhibits DNA methyltransferases (DNMT1, DNMT3A/3B). This traps DNMTs and leads to passive demethylation of DNA during cell division, causing global and gene-specific hypomethylation.
- RNA mechanism: Azacitidine is also incorporated into RNA as 5-aza-CTP, which can disrupt RNA processing and translation, contributing to cytotoxic/antiproliferative effects, especially at higher doses.

How this matters in GVHD
- Epigenetic reprogramming of immune cells:
- Demethylation can reactivate genes involved in immune tolerance, notably FOXP3, CTLA-4, IL-10, and TGF-β pathways.
- This favors differentiation and/or function of regulatory T cells (Tregs) and a less inflammatory T cell profile, which can dampen alloreactivity that drives GVHD.
- Modulation of effector cells and antigen presentation:
- Reduced expression of pro-inflammatory cytokines (e.g., IFN-γ, IL-2) by donor T cells.
- Possible changes in dendritic cell function and antigen presentation, leading to decreased alloimmune activation.
- Potential that GVL is preserved or enhanced:
- Hypomethylation can increase tumor antigen expression or HLA molecules in residual malignant cells, potentially maintaining graft-versus-leukemia effects while reducing GVHD.

Practical notes
- The immunomodulatory effects are dose- and schedule-dependent; low-dose, non-cytotoxic regimens are used in GVHD contexts to tilt toward tolerance rather than broad immunosuppression.
- Risks include cytopenias and infection; benefits depend on the patient and timing relative to transplant.

If you’d like, I can summarize recent studies or provide a simple schematic of the proposed T cell and DC changes in GVHD with azacitidine.